BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 14704816)

  • 1. [Immunomodulation in penetrating keratoplasty. Current status and perspectives].
    Pleyer U
    Ophthalmologe; 2003 Dec; 100(12):1036-44. PubMed ID: 14704816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
    Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
    Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of postoperative immunosuppression after keratoplasty in herpetic keratitis.
    Maier AK; Ozlügedik S; Rottler J; Heussen FM; Klamann MK; Huber KK; Joussen AM; Winterhalter S
    Cornea; 2011 Dec; 30(12):1398-405. PubMed ID: 21996945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evidences in immunosuppression in the maintenance of renal transplantation].
    Hernández D; González-Posada JM
    Nefrologia; 2005; 25(4):369-80. PubMed ID: 16231502
    [No Abstract]   [Full Text] [Related]  

  • 5. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 6. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study.
    Mayer K; Reinhard T; Reis A; Voiculescu A; Sundmacher R
    Graefes Arch Clin Exp Ophthalmol; 2003 Dec; 241(12):1051-4. PubMed ID: 12928902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease].
    Reisr A; Reinhard T; Voiculescu A; Mayer K; Sundmacher R
    Klin Monbl Augenheilkd; 2001 Mar; 218(3):183-6. PubMed ID: 11322055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Postoperative therapy after penetrating keratoplasty in herpes simplex keratitis].
    Süveges I; Füst Á; Imre L
    Orv Hetil; 2013 Dec; 154(52):2065-70. PubMed ID: 24374582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratoplasty postoperative treatment update.
    Shimmura-Tomita M; Shimmura S; Satake Y; Shimazaki-Den S; Omoto M; Tsubota K; Shimazaki J
    Cornea; 2013 Nov; 32 Suppl 1():S60-4. PubMed ID: 24104936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current practice of immune prophylaxis and therapy in perforating keratoplasty. A survey of members of the Cornea Section of the German Ophthalmological Society].
    Bertelmann E; Reinhard T; Pleyer U
    Ophthalmologe; 2003 Dec; 100(12):1031-5. PubMed ID: 14704815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk.
    Chatel MA; Larkin DF
    Am J Ophthalmol; 2010 Aug; 150(2):179-84. PubMed ID: 20570235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus use in de "novo renal" transplantation.
    Grinyo JM; Alonso A; Arias M; Campistol JM; González Molina M; González Posada JM; Morales JM; Oppenheimer F; Sánchez Fructuoso A; Sánchez-Plumed J; Ruiz JC
    Nefrologia; 2006; 26 Suppl 2():33-51. PubMed ID: 17937633
    [No Abstract]   [Full Text] [Related]  

  • 16. Pulmonary toxicity associated with sirolimus following kidney transplantation: computed tomography findings.
    Davaus Gasparetto T; Marchiori E; Menezes P; Zanetti G
    Nefrologia; 2010; 30(2):259-60. PubMed ID: 20393625
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunossupresive drugs in renal transplantation].
    Baczkowska T; Durlik M
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():99-120. PubMed ID: 15669207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus.
    Hunt SA
    Cardiol Rev; 2000; 8(3):180-4. PubMed ID: 11174892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.